Stakeholder perspectives and preferences for long-acting injectables for tuberculosis treatment and prevention: a multi-regional mixed-methods study

High stakeholder acceptability for long-acting injectables for tuberculosis was reported across WHO regions, with 83% (n=256) favoring LAIs over standard oral treatment.

• Why it matters: Product development and implementation need region-wide evidence on acceptability and regimen preferences, especially to address concerns that may differ by stakeholder group and lived TB experience.
• What they did: A sequential explanatory mixed-methods design combined online surveys (310 total; 102 Survey A, 208 Survey B) with focus group discussions, analyzing survey results using descriptive statistics, ordinal logistic regression, and one-sample proportion tests.
• The result: Preferred regimens included a three-month option with one month daily oral then four injections per monthly visit (69%) and the same with two injections per visit (80%); for prevention, 79% preferred a single injection, with lower interest linked to lived TB experience.

AI summary of the abstract · may contain errors · not medical advice · read the paper.